RCS - Frontier IP Group - Portfolio news - Strong results for TVG vaccine

Frontier IPAnnouncement

19/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260119:nRSS3139Pa&default-theme=true

RNS Number : 3139P  Frontier IP Group plc  19 January 2026

REACH - a non-regulatory announcement

AIM: FIPP

19 January 2026

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Strong results for TVG vaccine against zoonotic pig disease
Streptococcus suis

 

Frontier IP, a specialist in commercialising intellectual property, is
delighted to announce that a vaccine candidate to tackle Streptococcus suis
("S.suis") in pigs developed by portfolio company The Vaccine Group ("TVG" or
the "Company") has outperformed a leading commercially available vaccine in
challenge trials conducted by Moredun Scientific Limited ("MSL").

The results follow the outstanding success of the Company's bovine respiratory
syncytial virus ("BRSV") vaccine candidates in cattle announced in November
2025. In addition to demonstrating superior performance to an existing
vaccine, the results provide further strong validation for the TVG's
technology because:

·    they show TVG's underlying bovine herpesvirus vaccine delivery
platform is highly effective in animal species other than cattle

·    the bovine herpesvirus platform is able to combat different pathogens
and is effective against bacterial diseases, such as S.suis, as well as viral
diseases such as BRSV

The trial also showed TVG's vaccine is effective against different serotypes
of the disease.

S.suis is an economically damaging pig disease that can jump to humans,
causing meningitis, septicaemia and other symptoms. It is endemic in the
global pig population, estimated at 780 million strong, and affects up to 60
per cent of European pig farms.

Highly respected, MSL is among the foremost Contract Research Organisations
specialising in animal health and aquaculture in the UK.

TVG's vaccine evolved from a collaboration with two Chinese academic
institutions and the country's Pulike Biological Engineering Company.
Subsequent work was supported by further grant funding from Innovate UK. TVG
has also entered a collaboration with leading Spanish animal health group Syva
to develop a separate S.suis vaccine. Syva will have the option to license any
vaccine developed via the collaboration.

The Company is now in talks with major animal health companies over commercial
development of its BRSV vaccine candidates for use in cattle.

Jeremy Salt, TVG Chief Executive Officer, said: "These results show how useful
the BoHV-4 platform can be in delivering a wide range of efficacious vaccines
for livestock. One of the key issues with control of S. suis infection is the
ability to protect against multiple serotypes. In this study we have
demonstrated clearly that our candidate vaccine has this ability."

Frontier IP Chief Executive Officer Neil Crabb said: "We are delighted by
these results, which follow the outstanding success of TVG's BRSV vaccine
candidates. It is now clear the technology has broad applicability across
different animals and can be successful against both bacterial and viral
diseases. The Company is now in good stead to find the right industry partners
to bring its vaccines to market."

 

ENQUIRIES

            Frontier IP Group Plc
            Neil Crabb, Chief Executive                                             neil@frontierip.co.uk

            Andrew Johnson, Communications and investor relations                   M: 07415 888 425

            andrew.johnson@frontierip.co.uk

            Company website: www.frontierip.co.uk (http://www.frontierip.co.uk/)
            Allenby Capital Limited (Nominated Adviser)                             T: 0203 328 5656
            Nick Athanas

 The Vaccine Group                                                                  Jeremy.salt@thevaccinegroup.co.uk
 Jeremy Salt, CEO

ABOUT FRONTIER IP

Frontier IP unites science, finance and industry by identifying strong
intellectual property and accelerating its development through a range of
commercialisation services. A critical part of the Group's work is involving
relevant industry partners at an early stage of development to ensure
technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence
income by taking an active involvement in spin-out companies, including
support for fund raising and collaboration with relevant industry partners at
an early stage of development.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain. Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFITLFIRLIR



            Copyright 2019 Regulatory News Service, all rights reserved